Neovacs S.A. (EPA:ALNEV)

Market Cap	3.61K
Revenue (ttm)	823.43K
Net Income (ttm)	-35.45M
Shares Out	269.59K
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,508,557
Average Volume	1,228,778
Open	0.0150
Previous Close	0.0134
Day's Range	0.0150 - 0.0356
52-Week Range	0.0116 - 4,150.0000
Beta	-190.36
RSI	23.72
Earnings Date	Apr 30, 2025

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 22
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNEV

Financial Performance

In 2023, Neovacs's revenue was 533,412, an increase of 47868.71% compared to the previous year's 1,112. Losses were -8.74 million, 146.4% more than in 2022.